PDE5A and hypotensive disorder: In contrast to PDE5 inhibitors and sGC stimulators that infrequently cause systemic hypotension (i.e., in 8% (Rubin et al., 2011) and 10% (Rubin et al., 2015) of patients, respectively; Thenappan et al., 2018), β3 AR agonists do not decrease the systemic arterial pressure (Michel et al., 2020).